SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	96.36	16.27	15.85
Short-Term Investments	11.08	-	24.47
Cash & Short-Term Investments	107.44	16.27	40.32
Cash Growth	560.41%	-59.65%	-
Other Receivables	0.43	0.42	0.12
Total Trade Receivables	0.43	0.42	0.12
Other Current Assets	0.9	0.72	0.18
Total Current Assets	108.77	17.41	40.61
Net Property, Plant & Equipment	3.89	5.46	0.45
Other Long-Term Assets	3.21	0.45	0.09
Total Assets	115.87	23.32	41.15
Accounts Payable	2.7	1.98	0.64
Accrued Expenses	2.18	1.28	0.61
Current Portion of Leases	-	0.44	-
Other Current Liabilities	3.71	4.09	0.34
Total Current Liabilities	8.58	7.79	1.59
Long-Term Leases	1.58	3.46	-
Total Long-Term Liabilities	1.58	3.46	-
Total Liabilities	10.17	11.25	1.59
Common Stock	-	-	0
Additional Paid-in Capital	5.89	4.39	2.71
Retained Earnings	-104.73	-64.86	-35.7
Total Common Shareholders' Equity	-98.84	-60.47	-32.99
Minority Interest	-	-	72.55
Shareholders' Equity	-98.84	-60.47	39.56
Total Liabilities & Equity	115.87	23.32	41.15
Total Debt	1.58	3.9	0
Net Cash (Debt)	105.85	12.37	40.32
Net Cash Growth	755.66%	-69.31%	-
Net Cash Per Share	47.74	6.92	23.20
Book Value	-98.84	-60.47	-32.99
Book Value Per Share	-44.58	-33.82	-18.98
Tangible Book Value	-98.84	-60.47	-32.99
Tangible Book Value Per Share	-44.58	-33.82	-18.98

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q